Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials
| Autor: | Robin Goland, Brandon M. Nathan, Carmella Evans-Molina, Jay S. Skyler, Jay M. Sosenko, David Boulware, Susan Geyer, Peter G. Colman, Darrell M. Wilson, Mark A. Atkinson, William E. Russell, Antoinette Moran, John M. Wentworth, Diane K. Wherrett |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Blood Glucose 0301 basic medicine Research design medicine.medical_specialty endocrine system diseases Adolescent Endpoint Determination Endocrinology Diabetes and Metabolism medicine.medical_treatment 030209 endocrinology & metabolism Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Internal Medicine medicine Humans Cumulative incidence Epidemiology/Health Services Research Child Advanced and Specialized Nursing Type 1 diabetes Glucose tolerance test Framingham Risk Score C-Peptide medicine.diagnostic_test business.industry Insulin Infant Glucose Tolerance Test Middle Aged biochemical phenomena metabolism and nutrition medicine.disease 3. Good health Diabetes Mellitus Type 1 030104 developmental biology Endocrinology Child Preschool business Follow-Up Studies Cohort study |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | OBJECTIVE We assessed dysglycemia and a T1D Diagnostic Index60 (Index60) ≥1.00 (on the basis of fasting C-peptide, 60-min glucose, and 60-min C-peptide levels) as prediagnostic end points for type 1 diabetes among Type 1 Diabetes TrialNet Pathway to Prevention Study participants. RESEARCH DESIGN AND METHODS Two cohorts were analyzed: 1) baseline normoglycemic oral glucose tolerance tests (OGTTs) with an incident dysglycemic OGTT and 2) baseline Index60 RESULTS The cumulative incidence for type 1 diabetes was greater after IND/DYS− than after DYS/IND− (P < 0.01). Within the normoglycemic cohort, the cumulative incidence of type 1 diabetes was higher after DYS/IND+ than after DYS/IND− (P < 0.001), whereas within the Index60 CONCLUSIONS The findings suggest that incident dysglycemia without Index60 ≥1.00 is a suboptimal prediagnostic end point for type 1 diabetes. Measures that include both glucose and C-peptide levels, such as Index60 ≥1.00, appear better suited as prediagnostic end points. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|